As Medical Appliances & Equipment companies, Obalon Therapeutics Inc. (NASDAQ:OBLN) and Edwards Lifesciences Corporation (NYSE:EW) are our subject to compare. And more specifically their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Obalon Therapeutics Inc.	9.10M	3.72	37.38M	-2.02	0.00
Edwards Lifesciences Corporation	3.72B	10.62	722.20M	3.31	51.76

We can see in table 1 the earnings per share, top-line revenue and valuation of Obalon Therapeutics Inc. and Edwards Lifesciences Corporation.

Profitability

Table 2 provides Obalon Therapeutics Inc. and Edwards Lifesciences Corporation’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Obalon Therapeutics Inc.	-410.77%	-202.8%	-106.6%
Edwards Lifesciences Corporation	19.41%	22.4%	12.7%

Liquidity

Obalon Therapeutics Inc.?s Current Ratio is 1.7 while its Quick Ratio is 1.6. On the competitive side is, Edwards Lifesciences Corporation which has a 2.6 Current Ratio and a 1.9 Quick Ratio. Edwards Lifesciences Corporation is better positioned to pay off short and long-term obligations compared to Obalon Therapeutics Inc.

Analyst Ratings

The Ratings and Recommendations for Obalon Therapeutics Inc. and Edwards Lifesciences Corporation are featured in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Obalon Therapeutics Inc.	0	1	1	2.50
Edwards Lifesciences Corporation	2	4	9	2.60

$2.88 is Obalon Therapeutics Inc.?s average target price while its potential upside is 94.59%. Edwards Lifesciences Corporation on the other hand boasts of a $184.64 average target price and a -2.96% potential downside. Based on the analysts belief we can conclude, Obalon Therapeutics Inc. is looking more favorable than Edwards Lifesciences Corporation.

Institutional and Insider Ownership

Obalon Therapeutics Inc. and Edwards Lifesciences Corporation has shares held by institutional investors as follows: 56.4% and 88%. 2.8% are Obalon Therapeutics Inc.’s share held by insiders. On the other hand, insiders held about 0.1% of Edwards Lifesciences Corporation?s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Obalon Therapeutics Inc.	-15.89%	-1.64%	7.78%	-33.33%	-54.66%	-13.04%
Edwards Lifesciences Corporation	0.45%	0.46%	6.31%	19.04%	28.82%	11.78%

For the past year Obalon Therapeutics Inc. had bearish trend while Edwards Lifesciences Corporation had bullish trend.

Summary

On 12 of the 13 factors Edwards Lifesciences Corporation beats Obalon Therapeutics Inc.

Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. It offers the Obalon balloon system designed to provide weight loss in obese patients. Obalon Therapeutics, Inc. was founded in 2008 and is headquartered in Carlsbad, California.

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and their delivery systems for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral replacement, and minimally invasive aortic heart valve system; and tissue heart valves and repair products, which are used to replace or repair a patient’s diseased or defective heart valve. In addition, it produces pericardial valves from biologically inert animal tissue; and provides heart valve repair therapies, including annuloplasty rings and systems. Further, the company offers critical care products, such as hemodynamic monitoring systems to measure a patient’s heart function in surgical and intensive care settings; pulmonary artery catheters; and Oximetry Central Venous Catheters for continuous measurement of central venous oxygen saturation. Additionally, its critical care products include disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection; and peripheral vascular products used to treat endolumenal occlusive disease, such as embolectomy catheters for removing blood clots from peripheral blood vessels. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.